Salinas, CA, United States of America

Haresh Vazir

This inventor holds 1 USPTO granted patent. Top assignee: Pfizer Corporation. Active years: 2004.


Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Haresh Vazir: Innovator in Pharmaceutical Sciences

Introduction

Haresh Vazir is a notable inventor based in Salinas, CA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of non-peptide GnRH agents. His work focuses on addressing reproductive disorders and hormone-dependent tumors.

Latest Patents

Haresh Vazir holds 1 patent for his invention titled "Non-peptide GnRH agents, Pharmaceutical compositions, and methods for their use." This patent describes non-peptide GnRH agents that inhibit the effect of gonadotropin-releasing hormone. These agents are particularly useful for treating mammalian reproductive disorders and steroid hormone-dependent tumors, as well as for regulating fertility when suppression of gonadotropin release is indicated.

Career Highlights

Vazir is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His role at Pfizer allows him to contribute to innovative solutions in healthcare and medicine. His expertise in pharmaceutical compositions has positioned him as a valuable asset in the industry.

Collaborations

Throughout his career, Haresh Vazir has collaborated with notable colleagues, including Lance Christopher Christie and Mark Brian Anderson. These collaborations have further enhanced his research and development efforts in the pharmaceutical field.

Conclusion

Haresh Vazir's contributions to pharmaceutical sciences, particularly through his patent on non-peptide GnRH agents, highlight his innovative spirit and dedication to improving healthcare solutions. His work continues to impact the treatment of reproductive disorders and hormone-related conditions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…